
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Details : GF-CART01 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 25, 2024
